Skip to main content
Clinical Trials/NCT05514405
NCT05514405
Recruiting
Not Applicable

Effect of Remimazolam and Propofol on Postoperative Delirium in Elderly Patients Undergoing Hip and Knee Surgery

Inje University1 site in 1 country82 target enrollmentAugust 1, 2022

Overview

Phase
Not Applicable
Intervention
Remimazolam (Byfavo)
Conditions
Hip Fractures
Sponsor
Inje University
Enrollment
82
Locations
1
Primary Endpoint
Incidence of delirium 3 days after the end of operation
Status
Recruiting
Last Updated
10 months ago

Overview

Brief Summary

Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, hemodynamic stability compared to propofol gives clinicians preference to use for geriatric anesthesia. However, the study on the effect of remimazolam compared to propofol on postoperative delirium have not been carried out. The purpose of the study is to compare the incidence of postoperative delirium and recovery profile in elderly patients undergoing orthopedic surgery using either remimazolam or propofol.

Registry
clinicaltrials.gov
Start Date
August 1, 2022
End Date
December 31, 2025
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

In-Jung Jun

assisstant professor

Inje University

Eligibility Criteria

Inclusion Criteria

  • elderly patients undergoing hip or knee arthroplasty under general anesthesia.
  • body mass index \>30 kg/m2

Exclusion Criteria

  • moderate to severe liver dysfunction
  • moderate to severe renal dysfunction
  • unable to extubate in the operation room after operation
  • benzodiazepine dependence
  • sensitivity to anesthetic drugs used for study (Benzodiazepines, Propofol, Remifentanil, Fentanyl citrate, Rocuronium bromide, Sugammadex, Flumazenil)
  • acute angle glaucoma
  • received (benzodiazepine, antianxiety drugs, antidepressant, antipsychotic drugs) within 24 hours.
  • acute psychotic depression
  • history stroke or cerebrovascular disease

Arms & Interventions

Remimazolam group

Remimazolam is started during induction of anesthesia at the rate of 6 mg/kg/hr and continued at the rate of 1 mg/kg/hr (within 0.3-2 mg/kg/hr). Remimazolam is stopped 20 minutes before end of operation.

Intervention: Remimazolam (Byfavo)

Propofol group

Propofol is continuously infused within 1-5 μg/mL.

Intervention: Propofol

Outcomes

Primary Outcomes

Incidence of delirium 3 days after the end of operation

Time Frame: Upto 3 days after surgery

delirium is evaluated preoperatively and 3 days after surgery using Mini-Mental State Examination

Secondary Outcomes

  • quality of recovery (QoR-15) 3 days after the end of the operation(Upto 3 days after surgery)

Study Sites (1)

Loading locations...

Similar Trials